Our top pick for
Beginners

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Posted
Travere Therapeutics, Inc is a biotechnology business based in the US. Travere Therapeutics shares (RTRX) are listed on the NASDAQ and all prices are listed in US Dollars. Travere Therapeutics employs 221 staff and has a trailing 12-month revenue of around USD$194 million.
Our top pick for
Beginners
Our top pick for
Active investors
Our top pick for
Building a portfolio
52-week range | USD$8.98 - USD$25.5 |
---|---|
50-day moving average | USD$23.9526 |
200-day moving average | USD$20.3382 |
Wall St. target price | USD$31.38 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | USD$-3.417 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Revenue TTM | USD$194 million |
---|---|
Gross profit TTM | USD$170.1 million |
Return on assets TTM | -6.61% |
Return on equity TTM | 0% |
Profit margin | -40.24% |
Book value | $5.907 |
Market capitalisation | USD$1.2 billion |
TTM: trailing 12 months
There are currently 4.8 million Travere Therapeutics shares held short by investors – that's known as Travere Therapeutics's "short interest". This figure is 1.6% up from 4.7 million last month.
There are a few different ways that this level of interest in shorting Travere Therapeutics shares can be evaluated.
Travere Therapeutics's "short interest ratio" (SIR) is the quantity of Travere Therapeutics shares currently shorted divided by the average quantity of Travere Therapeutics shares traded daily (recently around 265521.38121547). Travere Therapeutics's SIR currently stands at 18.1. In other words for every 100,000 Travere Therapeutics shares traded daily on the market, roughly 18100 shares are currently held short.
However Travere Therapeutics's short interest can also be evaluated against the total number of Travere Therapeutics shares, or, against the total number of tradable Travere Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Travere Therapeutics's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 Travere Therapeutics shares in existence, roughly 90 shares are currently held short) or 0.104% of the tradable shares (for every 100,000 tradable Travere Therapeutics shares, roughly 104 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Travere Therapeutics.
Find out more about how you can short Travere Therapeutics stock.
We're not expecting Travere Therapeutics to pay a dividend over the next 12 months.
Travere Therapeutics's shares were split on a 1:9 basis on 8 November 2011. So if you had owned 9 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Travere Therapeutics shares – just the quantity. However, indirectly, the new 800% higher share price could have impacted the market appetite for Travere Therapeutics shares which in turn could have impacted Travere Therapeutics's share price.
Over the last 12 months, Travere Therapeutics's shares have ranged in value from as little as $8.98 up to $25.5. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Travere Therapeutics's is 0.721. This would suggest that Travere Therapeutics's shares are less volatile than average (for this exchange).
Retrophin, Inc., a biopharmaceutical company, focuses on the identification, development, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences, NGLY1.org, and Alagille Syndrome Alliance for identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. Retrophin, Inc. was founded in 2011 and is headquartered in San Diego, California.
Everything we know about the Achilles Therapeutics plc IPO, plus information on how to buy in.
Everything we know about the SEMrush Holdings Inc IPO, plus information on how to buy in.
Everything we know about the ChargePoint IPO, plus information on how to buy in.
Everything we know about the Kaltura Inc IPO, plus information on how to buy in.
Everything we know about the Rocket Lab IPO, plus information on how to buy in.
Everything we know about the Soho House IPO, plus information on how to buy in.
Everything we know about the VIZIO IPO, plus information on how to buy in.
Everything we know about the IDW Media Holdings Inc IPO, plus information on how to buy in.
Everything we know about the Karooooo Ltd IPO, plus information on how to buy in.
Everything we know about the Connect Biopharma Holdings Limited IPO, plus information on how to buy in.